Table 1.
Patient Characteristics
| Variable | All diagnoses N (%) | Hematologic malignancies N (%) |
|---|---|---|
| Number of patients | 18,544 | 17,793 |
| Number of transplant centers | 170 | 167 |
| Male | 10,707 (58) | 10,290 (58) |
| Age, median (years, range) | 55 (18–83) | 56 (18–83) |
| Recipient race | ||
| White | 15,732 (85) | 15,205 (85) |
| Black/African American | 1,398 (8) | 1,250 (7) |
| Asian | 721 (4) | 685 (4) |
| Others/ Unknown | 696 (3) | 653 (4) |
| Karnofsky Score at transplant, 70–100 | 17,961 (97) | 17,253 (97) |
| Positive recipient CMV status | 11,790 (64) | 11,295 (63) |
| Sorror HCT-Comorbidity Index14† | ||
| 0 | 3,750 (20) | 3,575 (20) |
| 1–2 | 5,535 (30) | 5,343 (30) |
| 3–4 | 5,936 (32) | 5,692 (32) |
| ≥5 | 3,325 (18) | 3,183 (18) |
| Estimated household income in USD, median (range) | 57,573 (7,500->200,000) | 57,640 (7,500->200,000) |
| Disease indication and status for HCT | ||
| Acute Myelogenous Leukemia (AML) | 7,471 (40) | 7,471 (42) |
| CR-1 | 4,724 | 4,724 |
| CR-2 | 1,148 | 1,148 |
| CR-3+ or relapse/ refractory | 1,599 | 1,599 |
| Acute Lymphoblastic Leukemia (ALL) | 2,492 (13) | 2,491 (14) |
| CR-1 | 1,723 | 1,723 |
| CR-2 | 482 | 482 |
| CR-3+ or relapse/ refractory | 286 | 286 |
| Chronic Myelogenous Leukemia | 609 (3) | 609 (3) |
| Early | 75 | 75 |
| Intermediate | 264 | 264 |
| Advanced | 240 | 240 |
| Very advanced | 30 | 30 |
| Other acute leukemia | 212 (1) | 212 (1) |
| Other chronic leukemia | 389 (2) | 389 (2) |
| CR or PR | 298 | 298 |
| Stable disease | 57 | 57 |
| Progression/ relapse | 34 | 34 |
| Myelodysplastic Syndrome | 3,086 (17) | 3,086 (17) |
| Myeloproliferative Diseases | 723 (4) | 723 (4) |
| Non-Hodgkin Lymphoma | 1,892 (10) | 1,892 (11) |
| Hodgkin Lymphoma | 382 (2) | 382 (2) |
| Plasma Cell Disorders | 538 (3) | 538 (3) |
| Other Malignancy (Solid Tumors) | 19 (<1) | -- |
| Total nonmalignant diseases | 735 (4) | -- |
| Product type | ||
| BM | 2,808 (15) | 2,295 (13) |
| PBSC | 14,549 (78) | 14,335 (81) |
| PBSC + BM | 16 (<1) | 15 (<1) |
| Cord blood ± Others | 1,174 (6) | 1,148 (6) |
| Donor type | ||
| Unrelated donor | 10,685 (58) | 10,318 (58) |
| Matched sibling | 5,417 (29) | 5,166 (29) |
| Greater than one locus mismatched relative | 1,945 (10) | 1,841 (10) |
| Other | 500 (3) | 468 (3) |
| Unrelated BM or PBSC donor human leukocyte antigen match | ||
| 8/8 | 7,734 (81) | 7,462 (81) |
| 7/8 | 1,282 (13) | 1,234 (13) |
| ≤ 6/8 or not specified | 496 (6) | 474 (3) |
| Age of unrelated BM or PBSC donor, median (years, range) | 28 (18–64) | 28 (18–64) |
| BM or PBSC donor/recipient sex match | ||
| Male-male | 6,722 (39) | 6,454 (39) |
| Male-female | 4,259 (25) | 4,075 (24) |
| Female-male | 3,361 (19) | 3,228 (19) |
| Female-female | 3,000 (17) | 2,859 (17) |
| Unknown | 31 (<1) | 29 (<1) |
| Unrelated BM or PBSC donor age at transplant, years | ||
| Under 30 | 5,641 (59) | 5,435 (59) |
| 30 to 39 | 2,214 (23) | 2,139 (23) |
| 40 to 49 | 1148 (12) | 1,102 (12) |
| 50 and above | 446 (5) | 434 (5) |
| Unknown | 63 (<1) | 60 (1) |
| Unrelated BM or PBSC donor ethnicity | ||
| Hispanic or Latino | 535 (6) | 505 (6) |
| Not Hispanic or Latino | 4,314 (45) | 4,153 (45) |
| Unknown | 4,663 (49) | 4,512 (49) |
| Unrelated BM or PBSC donor race | ||
| White | 5,242 (55) | 5,045 (55) |
| Black/African American | 212 (2) | 193 (2) |
| Asian | 175 (2) | 164 (2) |
| Others/ Unknown | 3,883 (41) | 3,768 (21) |
| Positive Donor CMV status among BM or PBSC grafts | 7,903 (45) | 7,547 (45) |
| History of parity among BM or PBSC donor | 2,209 (13) | 2,123 (13) |
| Year of transplant | ||
| 2014 | 6,062 (33) | 5,835 (33) |
| 2015 | 6,213 (33) | 5,937 (33) |
| 2016 | 6,272 (34) | 6,021 (34) |
| Prior autologous stem cell transplant | 1,683 (9) | 1,675 (9) |
| Median follow-up of survivors, months (range) | 24 (1.5–51.8) | 24 (1.5–51.8) |
†
1 case with unknown HCT-comorbidity index at the time of transplantation
Abbreviations: ALL = Acute Lymphoblastic Leukemia; AML = Acute Myelogenous Leukemia; BM = Bone Marrow; CB = Cord Blood; CMV = Cytomegalovirus; CR= complete remission; HCT = Hematopoietic Cell Transplantation; PBSC = Peripheral blood Stem Cells; PR= partial remission.